ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer

Metastatic Castration-resistant Prostate Cancer (mCRPC) Clinical Trial

— ProBio  

Official title:

ProBio: An Outcome-adaptive and Randomized Multi-arm Biomarker Driven Study in Patients With Metastatic Prostate Cancer

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03903835
• Other study ID #: EudraCT No 2018-002350-78
• Status: Recruiting
• Phase: Phase 3
• Start date: February 1, 2019
• Est. completion date: December 2026

Study information

• Verified date: January 2024
• Source: Karolinska Institutet
• Contact: Berit Larsson, MSc
• Phone: +46 8 52482576
• Email: berit.larsson[@]ki.se
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

ProBio is an international, outcome-adaptive, multi-arm, open-label, multiple assignment randomized biomarker driven platform trial in patients with metastatic prostate cancer. Patients will be randomized to control or experimental treatment arms. Patients in the control arm will receive standard of care following national guidelines. Patients in the experimental arm will be randomized to treatments based on a biomarker signature inferred from diagnostic tissue or liquid biopsy profiling. The predefined biomarker signatures are tumor properties or mutations in genes/pathways with previously demonstrated clinical validity (e.g. prognostic value or association with treatment response). The biomarker signatures are identified using a hybridisation capture gene panel specifically designed for prostate cancer.

Description:

ProBio is an outcome-adaptive, multi-arm, open-label, multiple assignment randomised biomarker driven platform trial in patients with metastatic hormone-sensitive and castration-resistant prostate cancer. Patients will be randomised to control or experimental treatment class arms. Patients in the control arm will receive standard of care following national guidelines and will remain within the control arm throughout the course of the trial. Patients in the experimental arm will be randomised to a treatment class (consisting of one or multiple drugs) based on a biomarker signature. The biomarker signatures are defined as tumour properties or mutations in certain genes/pathways identified in the scientific literature as important in prostate cancer treatment response. The biomarker signatures are identified using a gene panel specifically designed for advanced prostate cancer. Alterations in the following genes/pathways or combinations thereof constitute the biomarker signatures: - Androgen receptor - DNA-repair deficiency - TP53 - TMPRSS2-ERG gene fusion - PI3K pathway alterations Patients in the experimental arm can be randomized to the following treatments classes: for mHSPC - AR signalling inhibitors (Abiraterone acetate, Enzalutamide, Apalutamide) - Taxane-based chemotherapy in combination with ARSi (Docetaxel plus Abiraterone acetate, or Darolutamide) - PolyADP Ribose Polymerase Inhibitors (Niraparib plus Abiraterone Acetate) for mCRPC - AR signalling inhibitors (Enzalutamide, Abiraterone acetate) - Poly ADP Ribose Polymerase Inhibitors (Niraparib plus Abiraterone acetate) - Selective AKT Inhibitor (Capivasertib plus Docetaxel) ProBio will use outcome-adaptive randomization, adapting the randomization based on the observed progression free survival (PFS) within biomarker signatures. Treatments will initially be assigned to patients based on the biomarker signatures for which that treatment is most likely to be effective. The trial will be analyzed within a Bayesian framework, which allows for calculations of the probability for each treatment that it is superior to standard of care within a given signature. Each experimental arm will be evaluated for efficacy relative to the control arm with the same biomarker signatures. Participants and treating physicians will be blinded to ctDNA profile of each patient. The biomarker signatures will thus not influence treatment choice among controls (reflecting today's standard of care). Further, ProBio will use the sequential multiple assignments trial (SMART) concept, where each patient who progresses within the trial will re-enter the trial and be re-assigned to another treatment based on the patient's current ctDNA profile. Patients will be withdrawn after in total maximal three randomized consecutive treatments after inclusion into the study. The randomization probabilities within the experimental arm are defined in proportion to the probability that each treatment is superior to standard of care within a given biomarker signature, and therefore change as data accumulates in the trial and knowledge accumulates for what biomarker signatures and specific treatments that are more probable to be effective. Trial results will be evaluated regularly by an independent data and safety monitoring board (DSMB). The DSMB will evaluate treatment-signature combinations with respect to: - Graduation for superiority: A treatment-biomarker signature combination will be graduated from the trial if it has a Bayesian predictive probability of success in a future confirmatory phase III trial exceeding a pre-specified threshold (85%). - Termination for futility: Treatment-biomarker signature combinations will be dropped from the trial for futility when success probabilities drop sufficiently low (less than 10% using a minimum of 20 patients assigned to the specific treatment-biomarker signature combination). - Alternatively, if the maximum sample size of 300 and 150 patients (for mHSPC and mCRPC, respectively) assigned to a treatment biomarker signature is reached without graduation for superiority, assignments to that combination will end. ProBio is a platform study. This means that new treatments and biomarker signatures can be added to the experimental arm in the future. This will be done after protocol amendments.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 750
• Est. completion date: December 2026
• Est. primary completion date: December 2026
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Man with histologically confirmed prostate adenocarcinoma, initiating systemic therapy for metastatic disease, encompassing newly diagnosed (i.e. de novo) hormone sensitive prostate cancer (mHSPC) or first-line castration resistant prostate cancer (mCRPC)
• Distant metastatic disease documented by positive bone scan or metastatic lesions on CT or MRI
• Adequate health as assessed by the investigator to receive all available treatments in the trial
• ECOG/WHO (Eastern Cooperative Oncology Group/ World Health Organization) performance score 0-2
• Adequate organ and bone marrow function
• Albumin greater than or equal to 28 g/L
• Able to understand the patient information and sign written informed consent

Exclusion Criteria:

• Other malignancies within 5 years except non-melanoma skin cancer
• Within 6 months of randomization: myocardial infarction, unstable angina, angioplasty, bypass surgery, stroke, TIA (transient ischemic attack), or congestive heart failure NYHA (New York Heart Association) class III or IV
• Uncontrolled hypertension
• Uncontrolled hypotension
• Received systemic therapy (with the exception of standard ADT) prior to study inclusion, for the CRPC indication
• Any severe acute or chronic medical condition that places the patient at increased risk of serious toxicity or interferes with the interpretation of study results
• Unable to comply with study procedures
• Current participation in another clinical trial that will be in conflict with the present study, administration of an investigational therapeutic or invasive surgical procedure within 28 days prior to study enrolment
• Patients who are unlikely to comply with the protocol
• Any condition or situation which, in the opinion of the investigator, would put the subject at risk, may confound study results, or interfere with the subjects participation in this study.
• Any medical condition that would make use of the study treatments contraindicated, according to the SmPC, e.g. significant heart or liver disease.

Related Conditions & MeSH terms

• Metastatic Castration-resistant Prostate Cancer (mCRPC)
• Prostatic Neoplasms

Intervention

Drug:
• Enzalutamide Oral Capsule
Detailed conditions for the use of the study treatments including dose and dosages are described in accordance with the marketing authorization in the SmPC (Summary of Product Characteristics).
• Abiraterone Oral Tablet
Detailed conditions for the use of the study treatment including dose and dosages are described in accordance with the marketing authorisation in the SmPC.
• Carboplatin
Carboplatin will be administered every 3rd week with an AUC (area under curve) = 5 with a dose calculated according to the Carboplatin AUC Dose calculation (Calvert formula):Dose (mg) = TargetAUC (mg/ml x min) x [GFR ml/min + 25].
• Cabazitaxel 60 mg Solution for Injection
Detailed conditions for the use of the study treatment including dose and dosages are described in accordance with the marketing authorisation in the SmPC.
• Docetaxel Injectable Solution
Detailed conditions for the use of the study treatment including dose and dosages are described in accordance with the marketing authorisation in the SmPC.
• Radium Chloride Ra-223
Detailed conditions for the use of the study treatment including dose and dosages are described in accordance with the marketing authorisation in the SmPC.
• Niraparib plus Abiraterone acetate plus Prednisone
Niraparib and Abiraterone acetate will be provided by Janssen and will be provided either as a fixed dose combination or as single agents. Detailed use of the study treatment including dose and dosages are described in the Investigator's brochures and SmPC.
• Capivasertib plus Docetaxel
Capivasertib is provided by AstraZeneca and will be given in combination with Docetaxel. All subjects will be given up to ten 21-day docetaxel cycles. All subjects will receive Capivasertib, which will be administered as tablets taken twice a day orally, on a 4 days on/3 days off continuous schedule, commencing cycle one, day 2, until disease progression.
• Apalutamide
Detailed conditions for the use of the study treatments including dose and dosages are described in accordance with the marketing authorization in the SmPC (Summary of Product Characteristics).
• Darolutamide
Detailed conditions for the use of the study treatments including dose and dosages are described in accordance with the marketing authorization in the SmPC (Summary of Product Characteristics).

Locations

Country	Name	City	State
Belgium	OLV Ziekenhuis Aalst	Aalst
Belgium	GZA Sint-Augustinus	Antwerp
Belgium	AZ Sint-Jan AV	Brugge
Belgium	AZ Sint-Lucas	Brugge
Belgium	Ziekenhuis Oost-Limburg	Genk
Belgium	AZ Jan Palfijn Ziekenhuis	Gent
Belgium	University Hospital Ghent	Ghent
Belgium	Jessa ziekenhuis	Hasselt
Belgium	AZ Groeninge	Kortrijk
Belgium	University Hospital Luik	Liège
Belgium	AZ Damiaan	Oostende
Belgium	VITAZ	Sint-Niklaas
Norway	Ålesund Sjukehus	Ålesund
Norway	Kreftsenter Kristiansand	Kristiansand
Norway	Akershus Universitetssykehus	Lørenskog
Norway	Stavanger Universitetssjukehus	Stavanger
Norway	Universitetssykehuset Nord-Norge Tromsö	Tromsø
Sweden	Södra Alvsborgs sjukhus	Borås
Sweden	Falu lasarett	Falun	Region Dalarna
Sweden	Länssjukhuset Ryhov - Onkologiska kliniken	Jönköping
Sweden	Länssjukhuset	Kalmar
Sweden	Centralsjukhuset Region Värmland	Karlstad
Sweden	Universitetssjukhuset Örebro	Örebro
Sweden	Capio St.Görans Hospital	Stockholm
Sweden	Karolinska University Hospital	Stockholm
Sweden	Länssjukhuset Sundsvall Härnösand	Sundsvall
Sweden	Norrlands Universitetssjukhus	Umeå
Sweden	Akademiska sjukhuset	Uppsala
Sweden	Hallands sjukhus Varberg	Varberg
Sweden	Centrallasarettet Onkologkliniken	Växjö
Switzerland	St. Claraspital	Basel
Switzerland	Universitätsspital Basel	Basel

Sponsors (6)

Lead Sponsor	Collaborator
Karolinska Institutet	AstraZeneca, Cancerfonden, Janssen Pharmaceutica N.V., Belgium, Kom Op Tegen Kanker, The Swedish Research Council

Countries where clinical trial is conducted

Belgium,  Norway,  Sweden,  Switzerland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Progression free survival (PFS) in mCRPC	Progression will be evaluated by the established international standards of the Prostate Cancer Working Group version 3 (PCWG3) and for soft tissue metastases (e.g. lung, liver and lymph nodes) according to the Response Evaluation Criteria in Solid Tumors (RECIST v. 1.1).	Until progressive disease or 60 months from start of treatment, whatever occurs first.
Primary	Progression free survival (PFS) in mHSPC	Time to development of castration-resistance, as defined by EAU guidelines (biochemical progression or radiologic progression)	From date of treatment start until the date of first documentation of progression, assessed up to 60 months
Secondary	Treatment response rate in mCRPC	Treatment response is evaluated according to PCWG3 and RECIST 1.1	4 months after treatment start
Secondary	Overall survival (OS)	OS is defined as time to death from any cause (overall and prostate cancer specific)	From enrolment to completion of study (60 months)
Secondary	Patient Reported Outcome Measures (PROM)	QoL will be assessed using the EORTC QLQ-C30 instrument	From enrolment to completion of study (60 months)
Secondary	Cost-effectiveness	Cost effectiveness will be assessed by using the EQ-5D-5L instrument to estimate health utilities. Treatment costs will be based on drug costs and reimbursement data.	From enrolment to completion of study (60 months)
Secondary	Number of Participants With Adverse Events as a Measure of Safety and Tolerability	Common Terminology Criteria for Adverse Events (CTCAE) developed and maintained by the US National Cancer Institute will be used to record adverse events	From enrolment to completion of study (60 months)
Secondary	Treatment response rate in mHSPC	Response rates at 6 months on therapy will be evaluated by the established standards of EAU Guidelines	6 months after treatment start